David Goren - Vaxil Bio CEO Chairman
| VXL Stock | CAD 0.01 0.00 0.00% |
Chairman
David Goren is CEO Chairman of Vaxil Bio
| Address | 3400 One First Canadian Place, Toronto, ON, Canada, M5X 1A4 |
| Phone | 416-227-9667 |
| Web | https://www.vaxil-bio.com |
Vaxil Bio Management Efficiency
The company has return on total asset (ROA) of (0.1018) % which means that it has lost $0.1018 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.2026) %, meaning that it generated substantial loss on money invested by shareholders. Vaxil Bio's management efficiency ratios could be used to measure how well Vaxil Bio manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.0003 in 2024. Return On Capital Employed is likely to drop to -0.3 in 2024. At this time, Vaxil Bio's Net Tangible Assets are fairly stable compared to the past year. Non Currrent Assets Other is likely to climb to about 88 K in 2024, whereas Total Assets are likely to drop slightly above 853.8 K in 2024.Similar Executives
| Found 6 records | CHAIRMAN Age | ||
| Patrick Ramsey | Bank of America | 55 | |
| Brian Moynihan | Bank of America | 65 | |
| Kathleen Taylor | Royal Bank of | 61 | |
| Brian Levitt | Toronto Dominion Bank | 71 | |
| Paul Donofrio | Bank of America | 64 | |
| Robert Dorrance | Toronto Dominion Bank | N/A | |
Management Performance
| Return On Equity | -0.2 | ||||
| Return On Asset | -0.1 |
Vaxil Bio Management Team
Elected by the shareholders, the Vaxil Bio's board of directors comprises two types of representatives: Vaxil Bio inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Vaxil. The board's role is to monitor Vaxil Bio's management team and ensure that shareholders' interests are well served. Vaxil Bio's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Vaxil Bio's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Yuval Avnir, Head CEO | ||
| Riva MD, Scientist Board | ||
| David Goren, CEO Chairman |
Vaxil Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Vaxil Bio a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.2 | ||||
| Return On Asset | -0.1 | ||||
| Current Valuation | 449.79 K | ||||
| Shares Outstanding | 136.98 M | ||||
| Shares Owned By Insiders | 8.16 % | ||||
| Shares Owned By Institutions | 0.01 % | ||||
| Number Of Shares Shorted | 3.73 K | ||||
| Price To Earning | (1.40) X | ||||
| Price To Book | 2.39 X | ||||
| EBITDA | (252) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Vaxil Stock Analysis
When running Vaxil Bio's price analysis, check to measure Vaxil Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxil Bio is operating at the current time. Most of Vaxil Bio's value examination focuses on studying past and present price action to predict the probability of Vaxil Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxil Bio's price. Additionally, you may evaluate how the addition of Vaxil Bio to your portfolios can decrease your overall portfolio volatility.